Indoco Remedies: unit Anacipher wins Anvisa approval in Brazil
Anacipher, a unit of Indoco Remedies, received Anvisa approval in Brazil for its clinical and bioanalytical facilities after an inspection in March–April 2026.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Indian pharmaceutical company Indoco Remedies said its subsidiary Anacipher has received approval from Brazil's regulator Anvisa for its clinical and bioanalytical facilities. The Anvisa inspection ran from March 30 to April 7, 2026.
The update concerns a single manufacturer and does not change the picture for the broader market, but it confirms that the facilities meet the requirements of one of Latin America's largest drug regulators.
why it matters
For investors the news has a narrow significance: it matters mainly to Indoco Remedies shareholders and to those tracking Indian drugmakers' expansion into the Brazilian market.
tags
instruments
sources
- Indoco Remedies Says Anacipher Receives Anvisa Brazil Approval For Clinical And Bioanalytical Facilities — Reuters, 27 October 2026 at 10:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗